Skip to main content

FDA Approvals

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

Vyxeos Now Indicated for Treatment of Pediatric Patients with AML

FDA Approvals, Lymphoma

FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma

FDA Approvals, Lymphoma

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Page 9 of 21
Results 81 - 90 of 202